Two Healthcare Stocks for the Value Investor's Watchlist in 2026

For the disciplined investor, healthcare presents a classic setup. Its strength is not in factories or land, but in intangible assets-patents and proprietary technology-that create wide economic moats. These moats are the bedrock of durable competitive advantage, allowing companies to earn high returns on capital for extended periods. As one analysis notes, the 20 best healthcare companies to own in 2026 all possess this intangible-asset edge, whether through drug patents or complex medical device designs that protect their product designs

.

This advantage is often cemented by high switching costs. Consider a hospital that has invested millions in a suite of integrated surgical robots. The cost and operational disruption of changing systems are immense, locking the customer into a single vendor. This dynamic, seen in companies like Intuitive Surgical, turns a large installed base into a powerful moat that is difficult for competitors to breach Intuitive Surgical's strong moat and growth prospects.

The core value principle remains unchanged: buying a dollar for fifty cents. This demands careful scrutiny of current valuations to ensure a margin of safety. The sector's long-term promise does not guarantee today's price is right. As the list of top healthcare companies suggests, they are strong choices for a watchlist, but investors should consider buying only when prices trade below a calculated fair value consider buying only when they're trading below our price/fair value estimate. The goal is not to chase a sector's momentum, but to identify individual businesses where the market price offers a clear discount to their intrinsic worth.

AbbVie: The Dividend King with a Decade of Guidance

For the value investor, AbbVie represents a classic compounder in the making. Its most visible hallmark is a rare financial discipline: a , a streak that qualifies it as a Dividend King. This isn't mere tradition; it's a tangible signal of consistent cash generation and management's confidence in the business's durability. A company can maintain such a record only if its underlying engine-the ability to generate reliable revenue and earnings-remains robust.

That engine is firing on all cylinders with a clear, multi-year runway. The company has provided long-term guidance, . This isn't a vague promise but a specific target backed by a portfolio of assets. Its two immunology powerhouses, Skyrizi and Rinvoq, are on track to become two of the world's top-selling drugs, . The business is also diversifying, with growth from schizophrenia treatment Vraylar and migraine medicine Qulipta, while its oncology segment is expected to rebound. This balanced pipeline provides a wide margin of safety against the loss of any single product.

The current valuation presents a potential entry point for a patient investor. While the stock has rallied, its price-to-earnings ratio sits at a level that offers a significant discount to its own history. For context, Johnson & Johnson, a peer often used for comparison, trades at a , . AbbVie's own valuation, though not explicitly cited here, is implied to be in a similar range of relative cheapness. This gap between a proven, growing business and a depressed multiple is the very definition of a margin of safety. It suggests the market may be pricing in near-term noise-like the upcoming price negotiations for Vraylar in 2027-while overlooking the decade-long growth trajectory. For the value investor, that's where the opportunity lies.

Intuitive Surgical: The Unassailable Moat at a Reasonable Price

For the value investor, Intuitive Surgical is the archetype of a durable compounder. Its strength is not in a single blockbuster drug, but in a physical and economic moat that is nearly impossible to replicate. The company's strong moat and growth prospects are built on a massive installed base of over 10,700 da Vinci surgical systems. This isn't just a large number; it's the foundation of a recurring revenue engine that locks hospitals into its ecosystem .

The switching costs here are formidable. Once a hospital invests in a suite of these complex robotic systems, the operational disruption, training expenses, and potential risk of changing platforms create a powerful inertia. This dynamic turns the installed base into a self-reinforcing advantage. Hospitals don't just buy a machine; they buy a workflow, a trained staff, and a network of support. This creates a powerful flywheel: more systems installed leads to more instrument sales and service contracts, which in turn funds further innovation and support, making the platform even more valuable and harder to leave.

The business model is designed for resilience. While the initial system sale is a significant capital investment, the recurring revenue from surgical instruments and service contracts is what truly compounds over time. These are high-margin, consumable sales that are directly tied to the volume of procedures performed on the installed base. This recurring stream provides predictable cash flow and protects the business from the volatility of one-time equipment sales. It is a classic example of a high-switching-cost model in action, a key source of competitive advantage for medical-device companies.

The investment case here is straightforward. The market is pricing in a company with a wide, defensible moat and clear growth prospects. For the value investor, the primary driver is not a deep discount to intrinsic value, but the quality of the business itself. When a company can compound earnings for decades by selling a product that is so deeply embedded in its customers' operations, the focus shifts from today's price to the durability of the earnings stream. Intuitive Surgical represents that rare combination: a wide moat that is likely to widen, and a growth trajectory that is built on the physical reality of its installed base.

Risks and the Value Investor's Guardrails

For all its strengths, the value investor must always keep one eye on the horizon for potential threats to a company's economic moat. The primary risk is the erosion of that intangible advantage through patent expirations or disruptive technological change. As the analysis of the top healthcare companies notes, their wide moats are built on intangible assets that provide a wide moat against competitors, whether through patents or proprietary technology. These are not permanent shields. The expiration of key drug patents, like 's did in 2023, inevitably opens the door to generic competition and revenue decline. For a patient investor, the key watchpoint is the execution of long-term growth guidance, like AbbVie's projecting high single-digit revenue growth through 2029. Success depends on the continued commercial dominance of its immunology portfolio and the successful launch of new products, all while navigating the patent cliffs of the future.

Execution is not the only challenge. Even with a durable moat, a company's stock price can be pulled down by broader market sentiment and interest rates. Defensive healthcare stocks often trade at premiums because of their predictable cash flows, but these multiples can compress during periods of market stress or rising yields. This creates a tension for the value investor: the business may be fundamentally sound, but the market's risk appetite can still dictate a lower valuation. For instance, while AbbVie's shares have rallied, , suggesting the market is not yet pricing in its full decade-long growth story. Yet, that gap could narrow if macro conditions shift.

The disciplined approach is to manage these risks through a margin of safety. This means not buying a stock simply because it's a "best company to own," but only when the price offers a clear discount to intrinsic value. The watchlist is a starting point, not a purchase order. For the value investor, the guardrail is patience. It is the willingness to wait for the right price, even as the business executes its plan, because the true reward comes from compounding at a discount.

Conclusion: A Patient Capital Approach

The analysis of AbbVie and Intuitive Surgical converges on a clear investment thesis for the value investor. Both companies exemplify the ideal: durable competitive advantages in a defensive sector. AbbVie's strength lies in its portfolio of intangible assets, including patents and proprietary technology, which create a wide moat that provides a wide moat against competitors. Intuitive Surgical's moat is physical and economic, built on a massive installed base that generates high-switching-cost recurring revenue. These are the kinds of businesses that compound value over decades.

The decision for a patient capital investor hinges on price. For AbbVie, the math appears to offer a margin of safety. While the stock has rallied, , Johnson & Johnson, which trades at a . This gap suggests the market may be pricing in near-term noise while overlooking a decade of guided growth. For Intuitive Surgical, the premium valuation is justified by the quality of its moat. Its growth prospects are built on a self-reinforcing ecosystem that is difficult to replicate, making the current price a reflection of its durable earnings power rather than a speculative bid.

The value investor's role is to be fearful when others are greedy and greedy when others are fearful. This watchlist of two healthcare leaders is not a call to action today, but a reminder of the discipline required. It is about focusing on intrinsic value over short-term noise, waiting for the right price, and then compounding capital in businesses with wide moats. In a sector where the future is written in patents and proprietary technology, that is the path to long-term wealth.